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Abstract
Background
Chronic active antibody mediated rejection (c-aABMR) is a major cause of long-term kidney
allograft loss. It is hypothesized that frequent sub-therapeutic exposure to immunosuppres-
sive drugs, in particular tacrolimus (Tac), is a risk factor for the development of c-aABMR.
The intra-patient variability (IPV) in Tac exposure may serve as a substitute biomarker for
underexposure and/or non-adherence. In this study, the association between Tac IPV and
the development of c-aABMR was investigated.
Methods
We retrospectively included 59 patients diagnosed with c-aABMR and compared them to
189 control patients matched for age, year of transplantation and type of kidney donor.
The Tac IPV was calculated from pre-dose tacrolimus concentrations measured over a 3
year period preceding the diagnosis of c-aABMR. The mean Tac predose concentrations
(C0), Tac IPV, renal allograft function and graft survival were compared between the
groups.
Results
Tac IPV was 24.4% for the cases versus 23.6% for the controls (p = 0.47). The mean Tac
C0 was comparable for the cases (5.8 ng/mL) and control patients (6.1 ng/mL, p = 0.08).
Only in the c-aABMR group a significant decline in both mean Tac C0 and allograft func-
tion over the timespan of 3 years was observed (p = 0.03 and p<0.001). Additionally, in
the group of c-aABMR patients a high IPV was associated with inferior graft survival (p =
0.03).
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Conclusions
A high Tac IPV per se does not predispose to the development of c-aABMR but is associ-
ated with inferior graft survival once c-aABMR is diagnosed.
Introduction
Despite a significant improvement in short-term kidney allograft survival in the past decade,
long-term kidney allograft survival has remained relatively unchanged[1]. Chronic active anti-
body mediated rejection (c-aABMR) contributes substantially to these disappointing long-
term transplantation outcomes[2, 3]. c-aABMR is believed to be the result of recurrent endo-
thelial activation by pre-existing or de novo anti-HLA antibodies leading to numerous patho-
logical abnormalities[4, 5]. It has been hypothesized that the development of c-aABMR is
partially attributable to poor adherence or inadequate maintenance immunosuppression[3, 6].
In most centers, tacrolimus (Tac) is the cornerstone of the maintenance immunosuppres-
sive regimen after renal transplantation[7]. Tac is a drug that requires frequent predose con-
centration monitoring to maintain therapeutic exposure[8]. It has a narrow therapeutic
window and displays considerable intra-patient variability (IPV). The Tac IPV is defined as
the fluctuation in Tac concentrations within an individual patient over a certain period of time
[9]. These fluctuations in Tac exposure may result in periodic excessive or insufficient expo-
sure, possibly leading to (nephro)toxicity or acute rejection. Many studies have reported an
association between a high Tac IPV and inferior graft outcomes[10]. Patients with more vari-
ability in Tac exposure were more likely to develop donor-specific anti-HLA antibodies, lose
their grafts and develop chronic histological lesions[3, 11–17]. In these studies, allograft failure
was often defined as a composite endpoint which included the diagnosis of c-aABMR[3, 6, 11,
12, 15, 18]. However, the association between Tac IPV and the development of c-aABMR has
never been analyzed separately. In this study, the association between Tac IPV and the risk of
c-aABMR was investigated.
Subjects and methods
Study population
For this retrospective case-control study, all kidney transplant recipients transplanted in our
center between 2000 and 2013 were eligible. The main inclusion criteria was the use of Tac as
maintenance immunosuppression for both cases and controls. The year 2000 was chosen
because then Tac became the CNI of choice in our center.
The standard immunosuppressive regimen did not include induction therapy before the
year 2006–2007. Thereafter, patients received induction therapy with basiliximab and were set
on a triple immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil and
prednisolone after transplantation. In the first year after transplantation prednisolone was
slowly tapered to 0 after 3 months. As per local protocol, the administration of Tac was slowly
tapered after the first 6 months and Tac C0 were aimed at levels between 5–7 ng/ml. There
were no other inclusion criteria regarding the use of other (maintenance) immunosuppressive
drugs. This retrospective study was reviewed and approved by the Institutional Ethics Com-
mittee from the Erasmus MC, Rotterdam, The Netherlands. Due to the retrospective nature of
the study no informed consent was needed.
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Patients diagnosed with histologically-proven (suspicious) c-aABMR were defined as cases.
The cases were selected from the pathology database at our center and were diagnosed after a
for-cause biopsy. The diagnosis of c-aABMR was made at time of biopsy by an experienced
renal pathologist based on the current Banff classification[19–21]. Patients were excluded if
insufficient data was available (see data collection).
As a control group we selected kidney transplant recipients that showed no evidence of c-
aABMR. All patients in the control group have had no clinical suspicion of c-aABMR until
point of inclusion. Additionally, if present, all previous biopsy results have been screened for
signs of (suspicious) c-aABMR. Controls were matched for age, year of transplantation, type of
kidney donor (deceased versus living) and a minimal graft survival which resembled the cases’
time to c-aABMR diagnosis. The matching process was performed by coding all patients, both
cases and controls, for the aforementioned factors. By means of an algorithm patients were
found to be a positive match if all 4 factors were alike. The matches were selected from the
transplantation database of our center. For every single c-aABMR case all possible matches
were included.
Data collection
Demographic and baseline transplantation characteristics were collected for all patients. These
characteristics were retrieved from the local transplantation database and complete for more
than 90%. In addition, data on absolute (i.e. nondose-corrected) tacrolimus whole-blood, pre-
dose concentrations were collected. Only Tac C0 measured after month 6 after transplantation
were included, to allow for stabilization of drug dosing[11, 12]. Furthermore, only Tac C0 sam-
pled during outpatient clinic visits were included to minimize bias from measurements made
during hospitalization.
Tac C0 were collected over a period of 3 years. A minimum of 8 out-patient clinical mea-
surements of Tac C0 over a minimal time period of 2 years was necessary per individual for an
adequate calculation of Tac IPV.
The mean Tac C0 exposure over the 3 years was calculated as well as the Tac C0 exposure
per year. The Tac IPV of the cases was calculated in the 3 year time period prior to c-aABMR
diagnosis (endpoint, t0). The IPV of the controls was calculated over a similar time period,
dependent on the matched cases’ time to endpoint (t0). The Tac IPV of interest for each patient
was calculated as follows:
f½ðXmean   X1Þ þ ðXmean   X2Þ . . .þ ðXmean   XnÞ  ng  Xmean  100
Formula 1. Formula used for calculating the intra-patient variability often also referred to
as mean absolute deviation (MAD)[9, 11]. Xmean is the mean Tac C0 of all available samples in
the 3 years prior to c-aABMR diagnosis. X1 represents the first available Tac C0 measurement,
X2 the second. . ., and so on.
Furthermore, estimated glomerular filtration rate (eGFR, MDRD) measurements were col-
lected at routine out-patient clinic controls[22]. Data was collected at the time of endpoint (t0)
and 1 (t-1), 2 (t-2), and 3 (t-3) years prior to the histological diagnosis of c-aABMR (or matched
controls endpoint). Data on allograft function was complete up to 90%.
Outcome
The association between Tac IPV and the development of c-aABMR was the primary outcome
of interest. Secondary outcomes were allograft function, the mean Tac C0 exposure and its
change over time for both the cases and controls. Additionally, the change in mean Tac C0
exposure per year and its relation to allograft function was assessed. Potential confounders
Tacrolimus IPV in c-aABMR
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such as age, sex, time to diagnosis and type of transplantation were analyzed as possible con-
tributing factors to high Tac IPV in patients with c-aABMR.
Statistical analysis
The baseline characteristics of both cases and controls are reported using summary statistics
and frequency tables for continuous and categorical variables. Differences between cases and
controls were analyzed by the Chi-square test for categorical variables and with independent
and paired sample t-test test for continuous variables, as appropriate. Additionally, several
clinical characteristics such as age, gender, type of transplantation, mismatch and time to c-
aABMR diagnosis were analyzed for association with Tac IPV in the c-aABMR cases. The
groups were divided based on the characteristic and IPV percentages were compared by
means of independent sample t-test. Linear regression was used to examine the correlation
between allograft function and mean Tac C0. Overall graft survival was assessed by Kaplan-
Meier survival analysis with log-rank statistics for difference. The software IBM SPSS statistics
21 was used to perform the statistical analysis. Variables were considered statistically signifi-
cant with a two-tailed P-value of<0.05.
Results
Patient characteristics
Two hundred and forty-eight renal transplant patients were identified for this study and
included for analysis. Fifty-nine patients were considered cases and the remaining 189 were
matched controls. The characteristics of cases and controls are displayed in Table 1. The
median time from kidney transplantation to c-aABMR diagnosis (t0, endpoint) was 6.1 (IQR
3.5–8.3) years. The follow-up for both cases and controls was 3 years. Matching was achieved
successfully as there were no differences between cases and controls with regard to age at
transplantation, donor type and year of transplantation. More importantly, no statistically sig-
nificant differences were found in mean eGFR (48 ml/min/1.73m2 cases vs. 50 ml/min/1.73m2
controls, p = 0.55) and mean Tac C0 (6.1 ng/ml vs. 6.1 ng/ml, p = 0.98) at starting point (t-3)
which was 3 years prior to c-aABMR diagnosis or matched controls endpoint. There was how-
ever a significant difference in gender with significantly more male patients in the c-aABMR
cases.
Tacrolimus intra-patient variability and mean tacrolimus predose
concentrations
For the calculation of Tac IPV on average 17 (8–33) Tac C0 measurements were available for
the cases and 15 (8–44) measurements for the controls. The number of available Tac C0 mea-
surements was significantly higher for the cases (p = 0.01). This slight but significant difference
could be explained by the increased number of out-patient clinic visits (related to impairment
of renal function or the appearance of proteinuria) prior to the for-cause biopsy, in the cases.
The mean Tac IPV was 24.4% (range: 12.0%-48.3%) in the cases and 23.6% (range: 9.7%-
46.3%) in the controls and showed no statistically significant difference (p = 0.47). We were
unable to identify any specific clinical characteristics, such as age, gender, type of transplanta-
tion (living or deceased) and time to c-aABMR diagnosis to be associated with a significant dif-
ference in IPV (Table 2).
Similarly, there was no significant difference in mean Tac C0 over the total 3 year period
(t-3-t0). The cases had a mean Tac C0 of 5.8 ng/mL [range: 3.3 ng/mL-8.5 ng/mL] versus a
mean Tac C0 of 6.1 ng/mL [range: 3.6 ng/mL-10.0 ng/mL] for the controls (p = 0.08).
Tacrolimus IPV in c-aABMR
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Table 1. Demographic and clinical characteristics.
Cases (n = 59) Controls (n = 189) p-value
Age, years, mean (sd) 49 (±13) 52 (±13) 0.23
Gender, n (%) Female 21 (36) 39 (21) 0.02
Male 38 (64) 150 (79)
Donor type, n (%) Deceased donor 19 (32) 41 (22) 0.10
Living donor 40 (68) 148 (78)
Donor age, years, mean (sd) 51 (±12) 51 (±13) 0.71
Previous Transplantation, n (%) Yes 12 (20) 24 (13) 0.15
No 47 (80) 165 (87)
Time of Transplantation, year 2000–2012 2000–2012
Time to diagnosis, years, median (IQR) 6.1 (3.5–8.3) -
Total HLA mismatch, median (IQR) 3 (2–5) 3 (3–5) 0.70
PRAa current, mean (range) 1.5 (0–8) 3.2 (0–96) 0.44
PRA peak, mean (range) 9.5 (0–62) 6.6 (0–80) 0.49
Previous BPARb, n (%) Yes 15 (25) 36 (19) 0.30
No 44 (75) 153 (81)
eGFR at t-3, ml/min/1.73m2, mean (sd) 48 (±12) 50 (±15) 0.55
Trough-level at t-3, ng/mL, mean (sd) 6.1 (±1.9) 6.1 (±1.7) 0.98
C0 measurements, n, mean (range) 17 (8–33) 15 (8–44) 0.01
Primary kidney disease, n (%) Diabetic 8 (13.6) 36 (19)
Nephropathy
Hypertensive 10 (16.9) 44 (23.3)
Nephropathy
IgA Nephropathy 3 (5.1) 12 (6.3)
Polycystic Kidney 10 (16.9) 24 (12.7)
Disease
FSGSc 3 (5.1) 8 (4.2)
Obstructive 1 (1.7) 7 (3.7)
Nephropathy
Unknown 3 (5.1) 11 (5.8)
Other 21 (35.6) 47 (25)
a PRA, Panel Reactive Antibody;
b BPAR, biopsy proven acute rejection (incl. borderline changes);
c FSGS, Focal Segmental Glomerulosclerosis
https://doi.org/10.1371/journal.pone.0196552.t001
Table 2. Clinical characteristics associated with IPV in c-aABMR cases.
Clinical characteristic Tac IPV, %, mean (sd) p-value
Age <50yrs (n = 29)
>50yrs (n = 30)
22.8% (±7.4)
25.9% (±7.4)
0.12
Gender Male (n = 38)
Female (n = 21)
24.9% (±7.7)
23.5% (±7.2)
0.51
Type of transplantation PM (n = 19)
Living (n = 40)
24.4% (±5.9)
24.4% (±8.2)
0.99
Mismatch Mismatch<3 (n = 31)
Mismatch>3 (n = 26)
24.1% (±7.1)
24.8% (±8.3)
0.72
Time to c-aABMR <2250 days (n = 30)
>2250 days (n = 29)
25.4% (±7.3)
23.3% (±7.7)
0.28
https://doi.org/10.1371/journal.pone.0196552.t002
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There was however a significantly declining trend noted in mean Tac C0 during the 3 years
preceding the diagnosis of c-aABMR among cases but not controls (Fig 1) (p = 0.02 for cases
versus p = 0.18 for controls). When mean Tac C0 was analyzed per year, patients who devel-
oped c-aABMR had a mean Tac C0 of 6.1 ng/mL between t-3-t-2, which fell to 5.8 (t-2-t-1) and
5.4 ng/mL (t-1-t-0) in the years thereafter. Controls had a similar mean Tac C0 to the cases
between t-3-t-2 (6.1 ng/mL; p = 0.98) which in the years thereafter showed no decline (6.3 ng/
mL (t-2-t-1) and 5.9 ng/mL (t-1-t-0)). The difference in mean Tac C0 in the year prior to end-
point (t-1-t-0) between the cases and controls was significant at a P-value of 0.03.
Allograft function
Cases and controls showed a similar allograft function at start of analysis (t-3) of 48 ml/min/
1.73m2 and 50 ml/min/1.73m2, respectively (p = 0.55). In the following years the cases had a
substantial decline in allograft function. The average eGFR of the cases deteriorated from 48
ml/min/1.73m2 3 years before the diagnosis of c-aABMR to 45 (t-2), 42 (t-1), and 32 ml/min/
1.73m2 (t0; Fig 2). The controls on the other hand had a stable decline in allograft function of
only 1 ml/min/1.73m2 per year. The average eGFR of the controls decreased from 50 (t-3) to 49
(t-2), to 48 (t-1), and to 47 ml/min/1.73m
2 (t0; Fig 2). The allograft function of cases and con-
trols did not differ significantly in the first 2 years of follow up (p = 0.55 at t-3 and p = 0.07 at
Fig 1. The tacrolimus (Tac) predose concentrations (C0) spread over the 3 years prior to c-aABMR diagnosis/matched controls endpoints (t0) for both c-
aABMR patients (cases) and controls. Tac C0 (t-3-t-2) was 6.1 (±1.94) ng/mL for both cases and controls. Tac C0 (t-2-t-1) was 5.8 (±1.59) ng/mL for the cases and
6.3 (±1.60) ng/mL for the controls. Tac C0 (t-1-t-0) was 5.4 (±1.43) ng/mL for the cases and 5.9 (±1.47) ng/mL for the controls.
https://doi.org/10.1371/journal.pone.0196552.g001
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t-2). However, in the 2 years thereafter the cases had a significantly inferior allograft function
compared to the controls (p = 0.005 at t-1 and p<0.001 at t0).
Linear regression analysis showed a positive association between increasing Tac C0 and a
better allograft function (by 10 ml/min/1.73m2, β: 0.30; CI: 0.10, 0.49; P = 0.003, Fig 3). This
correlation was not present for the controls (p = 0.49).
Allograft survival
To assess the association of intra-patient variability and Tac C0 with overall graft survival, the
patients were divided dichotomously based on the cohort’s mean IPV and C0. The average
IPV of the low IPV group (24%) was 18.5% and 30.4% for the high IPV group (>24%). Nota-
bly, a high IPV was significantly associated with inferior graft survival (13.3 years for24%
IPV vs. 11.2 for >24% IPV; log rank, p = 0.03)(Fig 4A). However, this association was only
present for the cases. The cases with a low IPV showed an average survival of 13.1 years com-
pared to only 9.9 years in cases with a high IPV (log rank, p = 0.04; Fig 4B). The controls had a
survival of 13.4 years (24% IPV) versus 11.6 years (>24%)(log rank, p = 0.31).
A similar analysis based on below or above average Tac C0 did not show any differences for
either the case or control group (12.7 years for5.9 ng/mL vs. 12.2 years; log rank, p = 0.66)
(Fig 5).
Fig 2. Allograft function of both patients with c-aABMR (cases) and controls. t-3, p = 0.55;
t0, p<0.001.
https://doi.org/10.1371/journal.pone.0196552.g002
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Fig 3. Association between tacrolimus (Tac) predose concentrations (C0) and allograft function for the c-aABMR patients (cases).
https://doi.org/10.1371/journal.pone.0196552.g003
Fig 4. Allograft survival. (A) allograft survival based on24% tacrolimus (Tac) intra-patient variability (IPV) vs.>24% Tac IPV of cases and controls combined,
(B) Allograft survival of c-aABMR cases based on24% Tac IPV vs.>24%.
https://doi.org/10.1371/journal.pone.0196552.g004
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Discussion
In this retrospective case-control study we tested the hypothesis that a high IPV of tacrolimus
predose concentrations is associated with a higher risk for developing chronic-active antibody
mediated rejection of the kidney allograft. However, we found that in cases with c-aABMR the
IPV for tacrolimus in the years prior to the diagnoses was similar to the IPV of matched
controls.
Fluctuations in Tac C0 are very common in the first weeks or months after transplantation
due to numerous causes such as drug-drug interactions, tapering of corticosteroid doses and/
or changes in gastro-intestinal motility. Typically however, after a couple of weeks or months
patients reach a more stable situation as the inter-occasion variability decreases. The differ-
ences in Tac C0 tend to get smaller over time. Fluctuations in Tac C0 in the maintenance phase
after transplantation may therefor represent suboptimal patient-adherence. The calculated
intra-patient variability of Tac C0 is considered a surrogate marker for non-adherence[9,
10, 23].
There are however several methods for the calculation of the fluctuation in Tac C0. One of
which is the variance (σ2). The variance is used for the quantification of the intrapatient vari-
ability by showing the data distribution around the mean[13, 15]. Another useful method to
determine the Tac IPV is by calculating the coefficient of variation (CV) [13, 24–28]. The CV
assesses the degree of variation of Tac C0 measurements. We however, have chosen to use the
Fig 5. Allograft survival based on tacrolimus (Tac) predose concentrations (C0)5.9 ng/mL vs. >5.9 ng/mL of c-aABMR patients (cases) and controls
combined.
https://doi.org/10.1371/journal.pone.0196552.g005
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mean absolute deviation (MAD) as a statistical measure for Tac IPV. Although the calculation
of Tac IPV by means of MAD or CV are quite similar, the MAD is less susceptible to outliers.
This is because the CV uses the squared deviation from the mean, whereas the MAD uses the
absolute deviation[9, 11].
However, as stated above, the time period over which Tac C0 are collected, is of greater
importance and should be taken into account when interpreting Tac IPV data. And even
though a great variation has been reported in literature, on average Tac IPV is between 15%
and 30% which is in line with our findings[11, 13, 24–28].
Borra et al. were the first to establish an association between high intra-patient variability in
Tac C0 and the increased risk of developing graft loss[11]. Similar results have been published
since[12–15, 29–31]. However, no evidence has been provided for a link between suboptimal
Tac patient-adherence in the years after transplantation and the risk for late antibody mediated
rejection of the renal allograft.
The current studies tend to rely on broad composite end-points consisting of a range of
diagnoses such as late acute rejection, transplant glomerulopathy, graft failure and/or death
with function[11–15]. It can be expected that considerably different results may be obtained
once the composite endpoint is modified, as previously shown by the extension study of Borra
et al[12]2. They demonstrated a substantially smaller effect size of Tac IPV on long-term allo-
graft outcomes after adjustment of the composite endpoint. Furthermore a majority of these
studies focus on IPV over a brief time span in the first year after transplantation while chronic
humoral rejection is usually diagnosed at an average of 4–6 years after transplantation.
The remainder of studies on this subject define non-adherence as self-reported drug-non-
compliance, clinical suspicions by the attending physician and/or repeated nonattendance at
clinic visits or laboratory testing[3, 14]. This information is usually not present in most medi-
cal records except when the graft outcome was unfavorable which may create a biased inter-
pretation of the results.
In this study, IPV in cases and matched controls was similar and could therefore not sup-
port the hypothesis that a high IPV is associated with an increased risk for the development of
chronic active antibody mediated rejection. These findings are in line with previous results
published by Halloran et al. where nonadherence was not significantly associated with late
chronic active antibody mediated rejection[32]. Similarly, Vanhove et al. observed that high
IPV of Tac predicted chronic allograft damage such as tubular atrophy and severe fibrosis but
not inflammation or transplant glomerulopathy lesions[16].
Although cases and controls in our study had similar Tac C0 and renal function at starting
point, the cases showed a significantly declining trend in both Tac C0 and renal function com-
pared to the controls. The controls had a mean Tac C0 which varied around 6 ng/mL whereas
the cases showed a gradual decline reaching Tac C0 of 5.4 ng/mL at endpoint. A similar devel-
opment was visible in renal function where the controls showed an average decline in renal
function of 1 ml/min/1.73m2 per year while the deterioration in graft function of the cases
gradually increased to 10 ml/min/1.73m2 in the year prior to c-aABMR diagnosis. The decline
in Tac C0 was significantly correlated to the decline in renal allograft function for the cases.
Most likely, these observations reflect the physicians inclination to taper Tac dosage after wit-
nessing a decline in allograft function, in an attempt to avoid presumed tacrolimus-related
nephrotoxicity. Unfortunately, the entries made in the medical records were not sufficiently
informative to support this conclusion with data.
Of interest is the significant association of an inferior graft survival for the c-aABMR
patients with a high IPV versus those with a low IPV. This association was not found for the
controls. This intriguing finding is in line with previous research suggesting poorer graft sur-
vival for patients with high IPV’s[11–15]. The explanation can only be speculative but it
Tacrolimus IPV in c-aABMR
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suggests that not the risk for development of c-aABMR is IPV-related but rather the subse-
quent severity of the ongoing humoral rejection. Adequate maintenance of Tac C0 seems to
provide a better control of the chronic antibody mediated rejection which carries in general a
poor prognosis for graft survival.
Our study does have several limitations. First, the causes of IPV cannot be determined due
to the retrospective nature of the study. Even though multiple factors are known to contribute
to a high IPV, nonadherence is considered a dominant cause[10, 16]. Secondly, external vali-
dation might not be possible while it is a single center study and may not reflect the transplant
population of other centers and their immunosuppressive regimen. However, the Tac C0 were
in range with what is considered common practice (6.1 ng/mL and 5.8 ng/mL).
In conclusion, we demonstrated that a high intra-patient variability of tacrolimus long-
term after kidney transplantation is not associated with the occurrence of chronic antibody
mediated rejection but unfavorably affects graft survival in patients with c-aABMR.
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